Elastic stock analysis: wide moat, strong expansion and balance sheet, plus buyback. Valuation suggests ~56% upside to $108.8 ...

StoneCo shifts to credit/banking earnings with deposit funding and maturing loans. Read here for a detailed investment ...

Relative performance for nearly all LifeSmart Portfolios benefited from underweight exposure to fixed income and, for most ...

PKW performed almost as well as S&P 500 since its inception. Read why I consider PKW ETF worth buying for those who look for ...

Cedar Creek Partners highlights the growth and adjusted earnings of ENDI Corp in its Q4 2025 update. Read the full analysis ...

Alvotech has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johnson's Stelara/Simponi, and Eylea.

Despite deteriorating earnings revisions and weak growth, Accenture's profitability remains outstanding. Check out why ACN ...

NVIDIA Corporation is a strong sell with a $27 price target by the end of 2027. Click here to read the latest analysis on ...

Cedar Creek was up 29.6%, net of fees and expenses, outperforming all the major indices we track. On the whole, as of the end ...

The National Association of Realtors (NAR) pending home sales index experienced its largest monthly loss since 2020, falling ...

TimesSquare Capital Management's Small Cap Growth strategy outperformed the Russell 2000 Growth Index in 4Q25. Read the full ...

Cedar Creek Partners details high-alpha returns in the expert market via positions like Exco Resources and Phi Group. Read ...